We are live on
!
Find out more
CBIO
Crescent Biopharma
CBIO
CBIO
58 hedge funds and large institutions have $82.9M invested in Crescent Biopharma in 2023 Q4 according to their latest regulatory filings, with 15 funds opening new positions, 13 increasing their positions, 13 reducing their positions, and 6 closing their positions.
New
Increased
Maintained
Reduced
Closed
454% more call options, than puts
Call options by funds: $382K | Put options by funds: $69K
150% more first-time investments, than exits
New positions opened: 15 | Existing positions closed: 6
59% more capital invested
Capital invested by funds: $52.1M → $82.9M (+$30.8M)
18% more funds holding
Funds holding: 49 → 58 (+9)
0.01% more ownership
Funds ownership: 0.54% → 0.55% (+0.01%)
0% more repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 13
Holders
58
Holders Change
+9
Holders Change %
+18.37%
% of All Funds
0.85%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
15
Increased
13
Reduced
13
Closed
6
Calls
$382K
Puts
$69K
Net Calls
+$313K
Net Calls Change
-$45K
Top Buyers
Top Sellers
| 1 |
Acadian Asset Management
Boston,
Massachusetts
|
-$471K |
| 2 |
Renaissance Technologies
New York
|
-$119K |
| 3 |
Two Sigma Investments
New York
|
-$84.7K |
| 4 |
Two Sigma Advisers
New York
|
-$83.3K |
| 5 |
Dimensional Fund Advisors
Austin,
Texas
|
-$66.8K |
